• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by 9 Meters Biopharma Inc. (Amendment)

    2/9/23 11:51:13 AM ET
    $NMTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NMTR alert in real time by email
    SC 13G/A 1 p23-0712sc13ga.htm 9 METERS BIOPHARMA, INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*
     

    9 Meters Biopharma, Inc.

    (Name of Issuer)
     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)
     

    654405208

    (CUSIP Number)
     

    December 31, 2022

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 11 Pages)

     

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 654405208 13G/APage 2 of 11 Pages

     

    1

    NAME OF REPORTING PERSON

    Adage Capital Partners, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    650,000

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    650,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    650,000

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.02%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     

    CUSIP No. 654405208 13G/APage 3 of 11 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Adage Capital Partners GP, L.L.C.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    650,000

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    650,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    650,000

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.02%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

     

     

    CUSIP No. 654405208 13G/APage 4 of 11 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Adage Capital Advisors, L.L.C.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    650,000

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    650,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    650,000

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.02%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

     

    CUSIP No. 654405208 13G/APage 5 of 11 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Robert Atchinson

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    650,000

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    650,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    650,000

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.02%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

    CUSIP No. 654405208 13G/APage 6 of 11 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Phillip Gross

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    650,000

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    650,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    650,000

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.02%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

    CUSIP No. 654405208 13G/APage 7 of 11 Pages

     

     

    Item 1(a). NAME OF ISSUER
      The name of the issuer is 9 Meters Biopharma, Inc. (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES
      The Company's principal executive offices are located at 4509 Creedmoor Road, Suite 201, Raleigh, NC 27612.
       
    Item 2(a). NAME OF PERSON FILING
      This statement is filed by:
       
      (i) Adage Capital Partners, L.P., a Delaware limited partnership ("ACP") with respect to the shares of Common Stock directly owned by it;
       
      (ii) Adage Capital Partners GP, L.L.C., a limited liability company organized under the laws of the State of Delaware ("ACPGP"), as general partner of ACP with respect to the shares of Common Stock directly owned by ACP;
       
      (iii) Adage Capital Advisors, L.L.C., a limited liability company organized under the laws of the State of Delaware ("ACA"), as managing member of ACPGP, general partner of ACP, with respect to the shares of Common Stock directly owned by ACP;
       
      (iv) Robert Atchinson ("Mr. Atchinson"), as managing member of ACA, managing member of ACPGP, general partner of ACP with respect to the shares of Common Stock directly owned by ACP; and
       
      (v) Phillip Gross ("Mr. Gross"), as managing member of ACA, managing member of ACPGP, general partner of ACP with respect to the shares of Common Stock directly owned by ACP.
       
      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."  Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.
       
      The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
      The address of the business office of each of the Reporting Persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.

     

    Item 2(c). CITIZENSHIP
      ACP is a limited partnership organized under the laws of the State of Delaware.  ACPGP and ACA are limited liability companies organized under the laws of the State of Delaware.  Messrs. Gross and Atchinson are citizens of the United States.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
      Common Stock, $0.0001 par value per share (the "Common Stock").

     

    Item 2(e). CUSIP NUMBER
      654405208

     

    CUSIP No. 654405208 13G/APage 8 of 11 Pages

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) ¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

      (g) ¨ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution: Not applicable.

       

     

     

    CUSIP No. 654405208 13G/APage 9 of 11 Pages

     

     

    Item 4. OWNERSHIP  
         
      A. Adage Capital Partners, L.P., Adage Capital Partners GP, L.L.C. and Adage Capital Advisors, L.L.C.
        (a) Amount beneficially owned:  650,000
        (b) Percent of class: 5.02%.  The percentage set forth in this Schedule 13G/A is calculated based upon a total of 12,955,481 shares of Common Stock outstanding as of November 3, 2022, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022 filed with Securities and Exchange Commission on November 8, 2022.
        (c) (i) Sole power to vote or direct the vote:  0
          (ii) Shared power to vote or direct the vote: 650,000
          (iii) Sole power to dispose or direct the disposition:  0
          (iv) Shared power to dispose or direct the disposition of:  650,000
               

     

    ACP has the power to dispose of and the power to vote the shares of Common Stock beneficially owned by it, which power may be exercised by its general partner, ACPGP.  ACA, as managing member of ACPGP, directs ACPGP's operations. Neither ACPGP nor ACA directly own any shares of Common Stock.  By reason of the provisions of Rule 13d-3 of the Act, ACPGP and ACA may be deemed to beneficially own the shares owned by ACP.

     

      B. Robert Atchinson and Phillip Gross
        (a) Amount beneficially owned:  650,000
        (b) Percent of class:  5.02%
        (c) (i) Sole power to vote or direct the vote:  0
          (ii) Shared power to vote or direct the vote:  650,000
          (iii) Sole power to dispose or direct the disposition:  0
          (iv) Shared power to dispose or direct the disposition:  650,000
               
    Messrs. Atchinson and Gross, as managing members of ACA, have shared power to vote the shares of Common Stock beneficially owned by ACP.  Neither Mr. Atchinson nor Mr. Gross directly own any shares of Common Stock.  By reason of the provisions of Rule 13d-3 of the Act, each may be deemed to beneficially own the shares beneficially owned by ACP.  
                 

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
      Not applicable.
       

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
      Not applicable.
       

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
      Not applicable.
       

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
      Not applicable.
       

     

    CUSIP No. 654405208 13G/APage 10 of 11 Pages

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
      Not applicable.
       

     

    Item 10. CERTIFICATION

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 654405208 13G/APage 11 of 11 Pages

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: February 9, 2023

     

    ADAGE CAPITAL PARTNERS, L.P.
    By:  Adage Capital Partners GP, L.L.C.,
    its general partner
     
    By:  Adage Capital Advisors, L.L.C.,
    its managing member
     
    /s/ Robert Atchinson
    Name:  Robert Atchinson
    Title: Managing Member
     
    ADAGE CAPITAL PARTNERS GP, L.L.C.
    By:  Adage Capital Advisors, L.L.C.,
    its managing member
     
    /s/ Robert Atchinson
    Name:  Robert Atchinson
    Title: Managing Member
     
    ADAGE CAPITAL ADVISORS, L.L.C.
     
    /s/ Robert Atchinson
    Name:  Robert Atchinson
    Title: Managing Member
     
    ROBERT ATCHINSON
     
    /s/ Robert Atchinson
    ROBERT ATCHINSON, individually
     
    PHILLIP GROSS
     
    /s/ Phillip Gross
    PHILLIP GROSS, individually

     

     

     

     

    Get the next $NMTR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NMTR

    DatePrice TargetRatingAnalyst
    7/8/2021$5.00Outperform
    BMO Capital Markets
    More analyst ratings

    $NMTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BMO Capital Markets initiated coverage on 9 Meters Biopharma with a new price target

      BMO Capital Markets initiated coverage of 9 Meters Biopharma with a rating of Outperform and set a new price target of $5.00

      7/8/21 7:33:42 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup initiated coverage on 9 Meters Biopharma with a new price target

      Citigroup initiated coverage of 9 Meters Biopharma with a rating of Buy and set a new price target of $3.00

      6/4/21 7:33:28 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Brookline Capital resumed coverage on 9 Meters Biopharma with a new price target

      Brookline Capital resumed coverage of 9 Meters Biopharma with a rating of Buy and set a new price target of $6.00

      3/25/21 11:52:35 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NMTR
    Leadership Updates

    Live Leadership Updates

    See more
    • Corium Pharma Solutions Appoints Mark Sirgo as Chief Executive Officer

      Corium Pharma Solutions, Inc. ("Corium Pharma Solutions" or "CPSI"), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, including transdermal modalities, today announced the appointment of Dr. Mark Sirgo as Chief Executive Officer and member of the Board of Directors. Dr. Sirgo is a pharmaceutical executive with over 35 years' experience in the industry, including founding and serving as the President, Chief Executive Officer, and Vice Chairman of BioDelivery Sciences International, Inc. ("BDSI"), a commercial-stage specialty pharmaceutical company focused on pain and addiction management. During his tenure at BDSI,

      1/17/23 8:00:00 AM ET
      $AGRX
      $GNTA
      $NMTR
      $PG
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Package Goods/Cosmetics
    • 9 Meters Biopharma Appoints Bethany Sensenig as Chief Financial Officer

      Formerly served as VP of Finance and Commercial Operations at Biogen with 20+ years of business and strategic financial leadership experienceRALEIGH, NC / ACCESSWIRE / January 18, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases announced today the Company has appointed Bethany Sensenig, MBA, CMA, as Chief Financial Officer."We're very pleased to have Ms. Sensenig join the 9 Meters team as Chief Financial Officer with over twenty years of business and strategic financial leadership experience at both early-stage and large biotechnology companies," said John Temperato, President & Chief

      1/18/22 8:00:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Appoints Sarah Liu as Chief Commercial Officer and Al Medwar as Senior Vice President of Investor Relations & Corporate Communications

      RALEIGH, NC / ACCESSWIRE / January 3, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR),a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, announced today the Company has appointed Sarah Liu, MBA, as Chief Commercial Officer and Al Medwar, MBA, as Senior Vice President, Investor Relations & Corporate Communications."We are very excited to have such talented individuals, each with lengthy and accomplished pharmaceutical and biotech backgrounds, join the 9 Meters team during this critical time of growth for our company," said John Temperato, President & Chief Executive Officer of 9 Meters Biopharma. "Ms. Liu's

      1/3/22 7:30:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NMTR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome

      RALEIGH, NC / ACCESSWIRE / May 30, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that the Board of Directors has accepted the resignation of John Temperato as President and Chief Executive Officer of the Company effective immediately.Mark Sirgo, Chairman of the Board of 9 Meters, stated, "On behalf of the Board of Directors, I want to thank John for his service and dedication to the Company." The Board of Directors has appointed Bethany Sensenig, Chief Financial Officer of 9 Meters, to serve as interim Chief Executive Officer in addition to her current responsibiliti

      5/30/23 9:25:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023

      RALEIGH, NC / ACCESSWIRE / May 15, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2023.John Temperato, President & Chief Executive Officer of 9 Meters Biopharma, commented: "We are enthusiastic about the potential of vurolenatide and NM-136 to deliver value to patients. We are exploring options to fund further advancement of these assets, including financing and other strategic alternatives."Clinical Development and Business HighlightsPresentations on vurolenatide and SBS at ASPEN 2

      5/15/23 5:15:00 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesity

      RALEIGH, NC / ACCESSWIRE / April 5, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced receipt of a written response from the U.S. Food and Drug Administration (FDA) on the request for a Type B pre-IND (Investigational New Drug) meeting on the planned pre-clinical development of NM-136 for the treatment of obesity. Based on the response, the Company currently plans to submit an IND to the FDA for this indication in the second half of 2023 based on the completion of the preclinical program. An approved IND is a prerequisite for conducting Phase 1 clinical studies of NM-136

      4/5/23 8:00:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NMTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Sensenig Bethany

      4 - 9 METERS BIOPHARMA, INC. (0001551986) (Issuer)

      4/21/23 5:08:33 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Sirgo Mark A

      4 - 9 METERS BIOPHARMA, INC. (0001551986) (Issuer)

      3/31/23 4:35:29 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Rice Yehuda Michael

      4 - 9 METERS BIOPHARMA, INC. (0001551986) (Issuer)

      3/31/23 4:28:24 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NMTR
    Financials

    Live finance-specific insights

    See more
    • 9 Meters Biopharma Provides Business Update and Reports Financial Results for Third Quarter 2022

      Positive final results from the vurolenatide Phase 2 VIBRANT study in short bowel syndrome (SBS) reaffirmed the efficacy and safety of vurolenatide and determined the Phase 3 dose and regimenClinical plans and activities are underway including site and patient recruitment to facilitate Phase 3 study initiation upon protocol finalization with FDA this quarterRALEIGH, NC / ACCESSWIRE / November 8, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the third quarter ended Septembe

      11/8/22 8:00:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Provides Business Update and Reports Financial Results for Second Quarter 2022

      Positive preliminary results from Phase 2 VIBRANT study of vurolenatide in short bowel syndrome announcedVurolenatide End-of-Phase 2 meeting with FDA on track for 3QCash balance as of June 30, 2022 of $29.5 million; additional $20 million from previously announced July debt financing extends cash runway into 4Q 2023RALEIGH, NC / ACCESSWIRE / August 15, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the second quarter ended June 30, 2022.John Temperato, President & Chief Exe

      8/15/22 7:00:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2022

      On track to report Phase 2 data for vurolenatide for short bowel syndrome and Phase 3 interim analysis for celiac disease in JuneCash balance as of March 31, 2022, of $37.2 million is expected to fund ongoing clinical programs and business operations into Q2 2023RALEIGH, NC / ACCESSWIRE / May 16, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the first quarter ended March 31, 2022.John Temperato, President & Chief Executive Officer of 9 Meters Biopharma, commented: "This is

      5/16/22 7:00:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NMTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by 9 Meters Biopharma Inc. (Amendment)

      SC 13G/A - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)

      2/7/24 7:40:26 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by 9 Meters Biopharma Inc. (Amendment)

      SC 13G/A - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)

      2/9/23 11:51:13 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by 9 Meters Biopharma Inc.

      SC 13G - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)

      7/8/22 4:57:05 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NMTR
    SEC Filings

    See more
    • SEC Form 25-NSE filed by 9 Meters Biopharma Inc.

      25-NSE - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)

      9/8/23 10:11:45 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by 9 Meters Biopharma Inc.

      144 - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)

      7/19/23 4:41:57 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Events That Accelerate or Increase a Direct Financial Obligation, Bankruptcy or Receivership, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Financial Statements and Exhibits

      8-K - 9 METERS BIOPHARMA, INC. (0001551986) (Filer)

      7/18/23 8:00:11 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care